Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1-MVA 5T4 vaccine
- Development stage
- Phase 1
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1-MVA 5T4 is a viral vector-based cancer vaccine designed to stimulate an immune response against the oncofetal antigen 5T4, which is expressed in various cancers including prostate cancer. The vaccine uses a prime-boost strategy involving two replication-deficient viral vectors: chimpanzee adenovirus (ChAdOx1) for priming and modified vaccinia Ankara (MVA) for boosting. This approach aims to induce both T cell and antibody responses specific to the 5T4 antigen. Developed by Barinthus Biotherapeutics (formerly Vaccitech) in collaboration with the University of Oxford, it has shown immunogenicity and tolerability in early-phase clinical trials for prostate cancer[3][2][1]. The highest reported development phase is Phase II for prostate cancer[3].
- Other names
- Prostate cancer vaccine - Barinthus Biotherapeutics
02
Targets
TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on ChAdOx1-MVA 5T4 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1-MVA 5T4 vaccine.